Medindia

X

Impax to Present at Upcoming Investor Conferences

Monday, February 27, 2017 General News J E 4
Advertisement

FORT WASHINGTON, Pa., Feb. 27, 2017 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it plans to participate at the following upcoming investor conferences.

  • Raymond James and Associates' 38th Annual Institutional Investors Conference at 11:35 a.m. ET on March 6, 2017 in Orlando, FL.
  • Cowen and Company 37th Annual Health Care Conference at 8:00 a.m. ET on March 7, 2017 in Boston, MA.
  • Barclays Global Healthcare Conference at 8:30 a.m.ET on March 16, 2017 in Miami, FL.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com.  This presentation will be archived on the Company's web site for 90 days.

About Impax Laboratories, Inc.Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Company Contacts:     Mark DonohueInvestor Relations and Corporate Communications  (215) 558-4526  www.impaxlabs.com

Logo - http://photos.prnewswire.com/prnh/20150310/180590LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/impax-to-present-at-upcoming-investor-conferences-300413847.html

SOURCE Impax Laboratories, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Larry MacGirr of Pharmascience Elected Chair of Ca...
S
RegeneRx Licensee Receives FDA Permission to Condu...